Zevra Therapeutics (ZVRA) Depreciation & Amortization (CF) (2014 - 2026)

Zevra Therapeutics has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at $368000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 77.68% year-over-year to $368000.0; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (down 57.18% YoY), and the FY2025 full-year result was $4.1 million, down 36.55% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $368000.0, up from $362000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.7 million in Q2 2025, with the low at $62000.0 in Q3 2023.
• Historically, Depreciation & Amortization (CF) has averaged $750647.1 across 5 years, with a median of $392000.0 in 2025.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) slumped 84.42% — and 2024, when it surged 2508.06%.
• Zevra Therapeutics' Depreciation & Amortization (CF) stood at $300000.0 in 2022, then soared by 162.33% to $787000.0 in 2023, then surged by 109.4% to $1.6 million in 2024, then slumped by 78.03% to $362000.0 in 2025, then climbed by 1.66% to $368000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $368000.0 (Q1 2026), $362000.0 (Q4 2025), and $392000.0 (Q3 2025), per Business Quant data.